Sylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.
Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, NYU Langone Medical Center, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.
Adams says this is a powerful combination. The anti-CTLA4 agent helps to unleash the immune response and invigorates the response, while anti-PD-L1 agents can further stimulate the T cell response. Overall, these are powerful immunotherapeutics, Adams says, and have demonstrated their ability in other cancers, such as melanoma.
In breast cancer, anti-PD-L1 therapy has already been approved for the treatment of patients with triple-negative breast cancer, but there is no approval for routine use of this therapy in breast cancer. These agents also tend to carry some toxicity, so Adams says she tries to limit use of this therapy to patients in trials that have poor prognosis.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More